Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial

M. C. Kurth, Charles Howard Adler, M. St. Hilaire, C. Singer, C. Waters, P. LeWitt, D. A. Chernik, E. E. Dorflinger, K. Yoo

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

Tolcapone is a potent catechol-O-methyltransferase inhibitor that prolongs the plasma half-life of levodopa. This multicenter, double-blind, placebo-controlled study used two 10-hour clinical evaluations to compare the efficacy and safety of three doses of tolcapone (50, 200, and 400 mg tid) with placebo in patients with Parkinson's disease (PD) experiencing motor fluctuations from levodopa/carbidopa. One hundred fifty-one patients completed the study. Clinical evaluations lasting 10 hours were performed on day -1 and day 42 using United Parkinson's Disease Rating Scale motor subscale and 'on/off' and dyskinesia assessments every 30 minutes. Tolcapone significantly reduced 'off' time an average of 40% and increased total 'on' time by about 25% at all dose levels, as compared to placebo treatment. Levodopa/carbidopa dosage and frequency were significantly reduced. Tolcapone was well tolerated, with patients experiencing typical dopaminergic side effects that could be reduced or eliminated by lowering levodopa/carbidopa dosages. Tolcapone was effective at prolonging the clinical benefit of levodopa and reducing total levodopa requirements in PD patients with motor fluctuations.

Original languageEnglish (US)
Pages (from-to)81-87
Number of pages7
JournalNeurology
Volume48
Issue number1
StatePublished - Jan 1997

Fingerprint

Levodopa
Parkinson Disease
Randomized Controlled Trials
Placebos
Dopamine Agents
Dyskinesias
Half-Life
tolcapone
Safety
levodopa drug combination carbidopa

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations : A multicenter, double-blind, randomized, placebo-controlled trial. / Kurth, M. C.; Adler, Charles Howard; St. Hilaire, M.; Singer, C.; Waters, C.; LeWitt, P.; Chernik, D. A.; Dorflinger, E. E.; Yoo, K.

In: Neurology, Vol. 48, No. 1, 01.1997, p. 81-87.

Research output: Contribution to journalArticle

Kurth, M. C. ; Adler, Charles Howard ; St. Hilaire, M. ; Singer, C. ; Waters, C. ; LeWitt, P. ; Chernik, D. A. ; Dorflinger, E. E. ; Yoo, K. / Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations : A multicenter, double-blind, randomized, placebo-controlled trial. In: Neurology. 1997 ; Vol. 48, No. 1. pp. 81-87.
@article{eab871dce64c4a12b06161beebf88fb5,
title = "Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial",
abstract = "Tolcapone is a potent catechol-O-methyltransferase inhibitor that prolongs the plasma half-life of levodopa. This multicenter, double-blind, placebo-controlled study used two 10-hour clinical evaluations to compare the efficacy and safety of three doses of tolcapone (50, 200, and 400 mg tid) with placebo in patients with Parkinson's disease (PD) experiencing motor fluctuations from levodopa/carbidopa. One hundred fifty-one patients completed the study. Clinical evaluations lasting 10 hours were performed on day -1 and day 42 using United Parkinson's Disease Rating Scale motor subscale and 'on/off' and dyskinesia assessments every 30 minutes. Tolcapone significantly reduced 'off' time an average of 40{\%} and increased total 'on' time by about 25{\%} at all dose levels, as compared to placebo treatment. Levodopa/carbidopa dosage and frequency were significantly reduced. Tolcapone was well tolerated, with patients experiencing typical dopaminergic side effects that could be reduced or eliminated by lowering levodopa/carbidopa dosages. Tolcapone was effective at prolonging the clinical benefit of levodopa and reducing total levodopa requirements in PD patients with motor fluctuations.",
author = "Kurth, {M. C.} and Adler, {Charles Howard} and {St. Hilaire}, M. and C. Singer and C. Waters and P. LeWitt and Chernik, {D. A.} and Dorflinger, {E. E.} and K. Yoo",
year = "1997",
month = "1",
language = "English (US)",
volume = "48",
pages = "81--87",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations

T2 - A multicenter, double-blind, randomized, placebo-controlled trial

AU - Kurth, M. C.

AU - Adler, Charles Howard

AU - St. Hilaire, M.

AU - Singer, C.

AU - Waters, C.

AU - LeWitt, P.

AU - Chernik, D. A.

AU - Dorflinger, E. E.

AU - Yoo, K.

PY - 1997/1

Y1 - 1997/1

N2 - Tolcapone is a potent catechol-O-methyltransferase inhibitor that prolongs the plasma half-life of levodopa. This multicenter, double-blind, placebo-controlled study used two 10-hour clinical evaluations to compare the efficacy and safety of three doses of tolcapone (50, 200, and 400 mg tid) with placebo in patients with Parkinson's disease (PD) experiencing motor fluctuations from levodopa/carbidopa. One hundred fifty-one patients completed the study. Clinical evaluations lasting 10 hours were performed on day -1 and day 42 using United Parkinson's Disease Rating Scale motor subscale and 'on/off' and dyskinesia assessments every 30 minutes. Tolcapone significantly reduced 'off' time an average of 40% and increased total 'on' time by about 25% at all dose levels, as compared to placebo treatment. Levodopa/carbidopa dosage and frequency were significantly reduced. Tolcapone was well tolerated, with patients experiencing typical dopaminergic side effects that could be reduced or eliminated by lowering levodopa/carbidopa dosages. Tolcapone was effective at prolonging the clinical benefit of levodopa and reducing total levodopa requirements in PD patients with motor fluctuations.

AB - Tolcapone is a potent catechol-O-methyltransferase inhibitor that prolongs the plasma half-life of levodopa. This multicenter, double-blind, placebo-controlled study used two 10-hour clinical evaluations to compare the efficacy and safety of three doses of tolcapone (50, 200, and 400 mg tid) with placebo in patients with Parkinson's disease (PD) experiencing motor fluctuations from levodopa/carbidopa. One hundred fifty-one patients completed the study. Clinical evaluations lasting 10 hours were performed on day -1 and day 42 using United Parkinson's Disease Rating Scale motor subscale and 'on/off' and dyskinesia assessments every 30 minutes. Tolcapone significantly reduced 'off' time an average of 40% and increased total 'on' time by about 25% at all dose levels, as compared to placebo treatment. Levodopa/carbidopa dosage and frequency were significantly reduced. Tolcapone was well tolerated, with patients experiencing typical dopaminergic side effects that could be reduced or eliminated by lowering levodopa/carbidopa dosages. Tolcapone was effective at prolonging the clinical benefit of levodopa and reducing total levodopa requirements in PD patients with motor fluctuations.

UR - http://www.scopus.com/inward/record.url?scp=0031028464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031028464&partnerID=8YFLogxK

M3 - Article

C2 - 9008498

AN - SCOPUS:0031028464

VL - 48

SP - 81

EP - 87

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -